Celgene Corp

Trading Strategies

I Found Six Chances to Double Your Money by April 1

"Like finding a needle in a haystack."

Finding the right stocks in a market like this can be that way. There are around 4,000 stocks and almost as many funds. But only a relative few have what it takes to make you serious money.

You know the right ones are there… but they're all mixed in with the losers, and you don't know exactly what the right stocks "look like."

That's where my systems come in. They look at 10 years' worth of data on the top-performing 250 stocks and ETFs on the market to find only those stocks with a 90% or better chance of doubling your money.

But don't misunderstand: The stocks themselves don't have to double… Not at all. That could take forever, and I'm looking to book a 100% gain – make that six 100% gains – in five weeks at the outside.

Let's take a look. None of these stocks have to budge more than 10% for the doublers to start rolling in...


Get Your Hands on the World's First $1 Billion Cannabis Drug

When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.

You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.

Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.

And a number of successful drugs out there are rapidly approaching their patent cliffs.

That sounds bad.

But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.

For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.

So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.

Let's take a look...

Dow Jones

Dow Jones Today Rises Even as Government Shutdown Enters Third Day

The Dow Jones today dipped in early morning trading but investors are optimistic the start of earnings season will be better than expected thanks to the new tax reform bill.

Dow futures fell 59 points this morning as the government shutdown enters its third day. Bearish pundits are concerned the shutdown will overshadow a busy day of earnings reports and economic data.

Here's a look at today's most important market events and stocks, plus a look at today's economic calendar...


My Top Biotech Play for 2018 Could Make You 110.5% in 12 Months, If You Act Now

Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.

That's a correction, as defined by most market watchers.

And most investors – and their "enablers" on Wall Street – have shied away from biotech shares since. They're jittery.

In fact, I saw one august financial publication – the highly respected Investor's Business Daily – warn folks away from biotech in 2018 due to "median tenure of chief executives at large-cap biotech companies."

That's not just a stretch. It's a load of malarkey.

Here's the thing: If you want to double your money in 2018, you absolutely must invest in biotech.

That temporary dip in the iShares Nasdaq Biotechnology Index Fund ETF came after congressional Republicans ditched efforts to repeal and replace Obamacare. If there's one thing Wall Street hates, it's uncertainty.

As you might expect, Wall Street's panic led it to ignore some shares that have very bright futures – and are now trading at huge discounts.

So I've crunched the numbers – and done the research – and have identified three beaten-down biotech leaders that are poised to make huge comebacks throughout 2018.

I think you should put all three of these 2018 biotech comeback stocks on your "buy" list.

Especially the one that I believe will soar 110.5% in just 12 months...